X0508 4 2025-11-19 0 0001802768 Royalty Pharma plc RPRX 0001814899 Lloyd George W. C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET NEW YORK NY 10022 0 1 0 0 EVP, Investments & CLO 1 Class A Ordinary Shares 2025-11-19 4 S 0 47798 38.2788 D 10712 I By GWL 2023 G HoldCo LLC Class A Ordinary Shares 2025-11-19 4 S 0 4628 39.0077 D 6084 I By GWL 2023 G HoldCo LLC Class A Ordinary Shares 2025-11-19 4 S 0 47401 38.2787 D 4599 I By GWL 2020 G, LLC Class A Ordinary Shares 2025-11-19 4 S 0 4599 39.0071 D 0 I By GWL 2020 G, LLC Class A Ordinary Shares 2025-11-19 4 S 0 25530 38.2789 D 2470 I By GWL 2021 G, LLC Class A Ordinary Shares 2025-11-19 4 S 0 2470 39.0067 D 0 I By GWL 2021 G, LLC Class A Ordinary Shares 2025-11-19 4 S 0 2770 38.2858 D 230 D Class A Ordinary Shares 2025-11-19 4 S 0 230 39.0331 D 0 D Class A Ordinary Shares 495860 I By GWL 2013 NG, LLC Class A Ordinary Shares 220000 I By GWL 2014 G, LLC Class A Ordinary Shares 273960 I By IRA Class A Ordinary Shares 4011.19 I By Spouse All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.78 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. The Reporting Person also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares. /s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd 2025-11-21